CRBU supply chain intelligence for Caribou Biosciences, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Caribou Biosciences, Inc. (CRBU) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| INTELLIA-THERAPEUTICS-INC | INTELLIA-THERAPEUTICS-INC | 92% | we have primarily funded our operations through proceeds from the sales of our capital stock, revenue from our license and collaboration agreements, and proceeds from the sale of shares of Intellia T… |
| CMOS | CMOS | 90% | We expect to continue to rely on our CMOs for manufacturing our clinical trial materials |
| ADAPY | ADAPY | 72% | Reciprocal relationship from ADAPY graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whet… |
| ADAPY | ADAPY | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| ALLO | Allogene Therapeutics, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| ALLO | Allogene Therapeutics, Inc. | 72% | Reciprocal relationship from ALLO graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, wheth… |
| ARTV | Artiva Biotherapeutics, Inc. | 72% | Reciprocal relationship from ARTV graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from ARTV graph: uture environmental regulations may impair our research, development and pro… |
| ATRA | Atara Biotherapeutics, Inc. | 72% | Reciprocal relationship from ATRA graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, wheth… |
| ATRA | Atara Biotherapeutics, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| BMY | Bristol-Myers Squibb Company | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whethe… |
| DTIL | Precision BioSciences, Inc. | 72% | Reciprocal relationship from DTIL graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, wheth… |
| DTIL | Precision BioSciences, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| IOVA | Iovance Biotherapeutics, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| IOVA | Iovance Biotherapeutics, Inc. | 72% | Reciprocal relationship from IOVA graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, wheth… |
| LEGN | Legend Biotech Corporation | 72% | Reciprocal relationship from LEGN graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from LEGN graph: supply chain disruptions, failure of financial institutions, rising inflatio… |
| MGX | Metagenomi Therapeutics, Inc. | 72% | cts from countries where our product candidates may be sold at lower prices than in the United States. 60 Table of Contents Third-party payors, whether domestic or foreign, governmental or commercial… |
| MGX | Metagenomi Therapeutics, Inc. | 72% | Reciprocal relationship from MGX graph: amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, t… |
| NTLA | Intellia Therapeutics, Inc. | 72% | cts from countries where our product candidates may be sold at lower prices than in the United States. 60 Table of Contents Third-party payors, whether domestic or foreign, governmental or commercial… |
| NTLA | Intellia Therapeutics, Inc. | 72% | Reciprocal relationship from NTLA graph: Reciprocal relationship from CRBU graph: cts from countries where our product candidates may be sold at lower prices than in the United States. 60 Table of Co… |
| PRME | Prime Medicine, Inc. | 72% | Reciprocal relationship from PRME graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteris… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, wheth… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| RNAC | Cartesian Therapeutics, Inc. | 72% | Reciprocal relationship from RNAC graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, wheth… |
| RNAC | Cartesian Therapeutics, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ADAPY | ADAPY | 72% | Reciprocal relationship from ADAPY graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whet… |
| ADAPY | ADAPY | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| ALLO | Allogene Therapeutics, Inc. | 72% | Reciprocal relationship from ALLO graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from ALLO g… |
| ALLO | Allogene Therapeutics, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| ATRA | Atara Biotherapeutics, Inc. | 72% | Reciprocal relationship from ATRA graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, wheth… |
| ATRA | Atara Biotherapeutics, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whethe… |
| BMY | Bristol-Myers Squibb Company | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| DTIL | Precision BioSciences, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| DTIL | Precision BioSciences, Inc. | 72% | Reciprocal relationship from DTIL graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from DTIL g… |
| IOVA | Iovance Biotherapeutics, Inc. | 72% | Reciprocal relationship from IOVA graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from IOVA graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from IOVA g… |
| IOVA | Iovance Biotherapeutics, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| LEGN | Legend Biotech Corporation | 72% | Reciprocal relationship from LEGN graph: ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and employ complex logistical operations, i… |
| MGX | Metagenomi Therapeutics, Inc. | 72% | Reciprocal relationship from MGX graph: Reciprocal relationship from CRBU graph: cts from countries where our product candidates may be sold at lower prices than in the United States. 60 Table of Con… |
| MGX | Metagenomi Therapeutics, Inc. | 72% | cts from countries where our product candidates may be sold at lower prices than in the United States. 60 Table of Contents Third-party payors, whether domestic or foreign, governmental or commercial… |
| NTLA | Intellia Therapeutics, Inc. | 72% | mulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is recorded in the statements of operations. Repairs and maintenance are expensed as incurred. … |
| NTLA | Intellia Therapeutics, Inc. | 72% | Reciprocal relationship from NTLA graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from NTLA g… |
| PRME | Prime Medicine, Inc. | 72% | Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from REGN graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from REGN g… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| RNAC | Cartesian Therapeutics, Inc. | 72% | untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly so… |
| RNAC | Cartesian Therapeutics, Inc. | 72% | Reciprocal relationship from RNAC graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, wheth… |
| LIQUIDITY-CAPITAL-RESOURCES | LIQUIDITY-CAPITAL-RESOURCES | 62% | nd development of our product candidates will depend on a variety of factors, including: • sufficiency of our financial and other resources; • acceptance of our CRISPR chRDNA genome-editing technolog… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| CRBU-DEBT-8835 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2021-12-31. |
| CRBU-DEBT | Debt stack $26.9M | 90% | Market cache reports total debt of $26.9M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| CRBU-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 136 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| KALV | KalVista Pharmaceuticals, Inc. | 100.00 | 2 | |
| SGMO | Sangamo Therapeutics, Inc. | 100.00 | 2 | |
| IPSC | Century Therapeutics, Inc. | 100.00 | 2 | |
| TKPHF | Takeda Pharmaceutical Company Limited | 100.00 | 2 | |
| MGX | Metagenomi Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| ADAPY | Adaptimmune Therapeutics PLC | 100.00 | 1 | ['customer', 'supplier'] |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | ['customer', 'supplier'] |
| DTIL | Precision BioSciences, Inc. | 100.00 | 2 | ['customer', 'supplier'] |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | ['customer', 'supplier'] |
| ATRA | Atara Biotherapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| AUTL | Autolus Therapeutics plc | 100.00 | 2 | |
| CLLS | Cellectis S.A. | 100.00 | 2 | |
| BMY | Bristol-Myers Squibb Company | 100.00 | 2 | ['customer', 'supplier'] |
| CELU | Celularity Inc. | 100.00 | 2 | |
| BMYMP | Bristol-Myers Squibb Co | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| GSK | GSK plc | 100.00 | 2 | |
| CRSP | CRISPR Therapeutics AG | 100.00 | 2 | |
| RNAC | Cartesian Therapeutics, Inc. | 100.00 | 2 | ['customer', 'supplier'] |